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Introduction: Philadelphia chromosome (Ph) is a hallmark of chronic myeloid leukemia (CML), which exists in more
than 90% CML and in 3% to 40% acute lymphoblastic leukemia (ALL).
Case description: A 25-year-old man was diagnosed with CML in chronic phase. He first received treatment with
hydroxyurea, achieving hematological remission and following imatinib mesylate for main treatment. A year later,
he began to appear unexplained high fever with ineffective antibiotic treatment and bone morrow and blood tests
indicated blast crisis. Both BCR/ABL 210 and BCR/ABL 190 fusion transcript were positive. Imatinib resistance was
confirmed by a screening for ABL kinase domain E255K mutations, and dasatinib was administered. After two
months, the patient went on to hematological remission.
Discussion and evaluation: During medical treatment for CML, we experienced a relatively rare case with co-expression
of the p210 and p190 encoding BCR-ABL transcripts in blastic phase. Imatinib resistance was confirmed and remission
wasn’t easily obtained, yet dasatinib was helpful. When resistance emerges, the treatment options include increasing the
daily dose of imatinib, or combining imatinib with other agents. Of course, dasatinib, nilotinib and bone marrow
transplantation are good choice as well.
Conclusions: The presence of p-190 transcript in CML may be related to progression of the disease. Thus monitoring the
resistance of imatinib in CML patients, especially for advanced phase CML and BCR-ABL ALL, may be meaningful to guide
clinical treatment and predict the prognosis.
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Philadelphia chromosome (Ph) is a hallmark of chronic
myeloid leukemia (CML), which exists in more than 90%
CML and in 3% to 40% acute lymphoblastic leukemia
(ALL) (Westbrook et al. 1992). It derives from a recipro-
cal translocation between chromosome 9 and 22, t (9;
22) (q34; q11), which results in the fusion of the 3' part
of the ABL gene on chromosome 9 and the 5' part of
the BCR gene on chromosome 22 (Bartram et al. 1983).
In most Ph positive CML, the breakpoint in the BCR
gene occurs in a small 5.8 Kb major breakpoint cluster
region (M-bcr). This hybrid BCR-ABL gene in CML is* Correspondence: sunfbj@126.com
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in any medium, provided the original work is ptranscribed into a novel 8.5 kb mRNA with a b3a2 and/
or b2a2 junction. The mRNA encodes 210-kD fusion
protein that can enhance protein tyrosine kinase activity.
In the majority of Ph positive ALLs, the breakpoint is lo-
cated in the first intron of the BCR gene known as the
minor breakpoint cluster region (m-bcr).This fusion of
BCR exon 1 to ABL exon 2 (ela2) leads to a 7.0-kb mRNA
transcript that encodes the190-kD protein (Chissoe et al.
1995). Here, we report a patient co-expressed the p210
and p190 BCR-ABL transcripts in blast crisis.
Imatinib mesylate (IM), a new tyrosine kinase inhibitor,
specifically targets BCR-ABL, which brings revolutionary era
to the treatment of CML (Druker 2002, Savage and Antman
2002). Although the efficacy of IM is widely proved, resist-
ance to IM has become a pressing challenge in the treat-
ment of CML, especially in patients with advanced phasesan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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anisms of resistance have been described before, while the
presence of ABL kinase domain is the most frequent mech-
anism of acquired resistance.
Case report
A 25-year-old man was diagnosed as having a CML in
December 2012. At diagnosis, physical examination re-
vealed palpable spleen and liver. Laboratory tests showed
leukocytosis(137 × 109/L))with 2.5%myeloblasts,3.4%pro-
myelocytes, 87.1%neutrophils, 6% eosinophils, and 1%
basophils. The Hb was 11.3 g/dL and PLT 152 × 109/L.
Lactate dehydrogenase level was 2782 IU/dL. Bone mar-
row examination showed hypercellularity with myeloid
hyperplasia with 2.4% myeloblasts, 2.8% promyelocytes,
20% myelocytes, 18% metamyelocytes, 6% eosinophils,
0% basophils (Figure 1). Peripheral blood smear and
bone marrow trephine showed the typical features of
chronic phase CML. Cytogenetic studies on marrow spe-
cimen showed a 46XY karyotype with t(9;22)(q34;q11) in
all of 20 metaphase cells. Ph-positive ratio in bone mar-
row cells analyzed by fluorescence in situ hybridization
(FISH) was 21.2% (Figure 2). The BCR/ABL 210 fusion
transcript was found by reverse transcriptase polymerase
chain reaction (RT-PCR) and BCR/ABL 190 fusion tran-
script wasn’t detected.
He was initially treated with hydroxyurea. About one
month later, he went on to hematological remission. Then
the patient was treated with imatinib mesylate (IM 400 mg,
qd) for more than one year. At 3, 6, 9 and 12 months after
diagnosis, BCR/ABL 210 fusion transcript detected by RT-
PCR was still positive and BCR/ABL 190 fusion transcript
was negative. In April 2014, he began to appear unexplainedFigure 1 Bone marrow examinations at initial diagnosis. (Wright-Giemhigh fever with ineffective antibiotic treatment and a rise in
WBC was detected. Bone marrow examination showed
hypercellularity with myeloid hyperplasia with 25% myelo-
blasts. Flow cytometry analysis showed blasts accounted
for 21.88% of the total cells and were positive for CD34,
CD38, HLA-DR, CD13, CD33, CD117, CD9 and negative
for MPO, cyCD3, cyCD79a, CD19, CD3, CD2, which sug-
gested this patient entered into blast crisis (BC). Both
BCR/ABL 210(0.83 BCRABL⁄ABL ratio) and BCR/ABL
190(0.001BCRABL⁄ABL ratio) fusion transcript were posi-
tive. He was treated with HA (HHA 4 mg d1-7,Ara-C
200 mg d1-7) and MA(MIT 10 mg d1-3, Ara-C 200 mg
d1-7) regimen. However, hematological remission was not
obtained. In June 2014, he was treated with HAG (HHA
2 mg d1-14, Ara-C 25 mg × 2 d1-14, G-CSF 300ug d1-14).
Fortunately, he could achieve partial hematological remis-
sion after this induction chemotherapy and BCR/ABL 190
fusion transcript Gene turned to negative. Imatinib
resistance was confirmed by a screening for ABL kinase
domain E255K mutations, and dasatinib was administered.
After two months, the patient went on to hematological
remission.
Discussion
It is generally thought that p210 BCR-ABL gene is ob-
served in most Ph-positive CML patients, while the break-
point in m-bcr is more frequently found in Ph-positive
ALL and it is generally associated with an acute leukemia
phenotype (Melo 1996). However, co-expression of the
p210 and p190 encoding BCR-ABL transcripts is relatively
rare. Some researchers indicated that the presence of p190
fusion gene was associated with a blastic phase as clinical
presentation of the disease in most CML patients (Costellosa staining, ×1000).
Figure 2 Interphase cells from CML marrow at diagnosis showing ABL (red signal), BCR (green signal) and BCR-ABL fusion (yellow signal).
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patient co-expressed the p210 and p190 BCR-ABL tran-
scripts in BC and remission wasn’t easily obtained, suggest-
ing that the presence of the p-190 transcript in CML may
be related to progression of the disease. However, it is worth
wondering whether the presence of the p-190 transcript ac-
counts for the resistance to imatinib treatment.
Several mechanisms that have been proposed may explain
the resistance to imatinib (Agirre et al. 2003, Gambacorti-
Passerini et al. 2000, Shah et al. 1998). Point mutations in
the kinase domain of ABL are recognized as the major
cause, especially in patients with advanced phase CML and
BCR-ABL ALL.
Up to now, more than 50 mutants have been researched
(Jabbour et al. 2006, Willis et al. 2005). Hochhaus et.al
demonstrated that the substitutions of E255 resulted in
virtual insensitivity to imatinib (Hochhaus et al. 2002).
Other researchers discovered that ATP binding (P) loop, a
highly conserved glycine rich sequence occupying residues
248-255 of ABL mutations, were related to a more rapid
progression to advanced-phase disease than mutations in
other regions (Soverini et al. 2005).
When resistance emerges, the treatment options in-
clude increasing the daily dose of imatinib, or combining
imatinib with other agents. Of course, if economic con-
ditions permit, more potent kinase inhibitors, such as
dasatinib and nilotinib. and bone marrow transplant-
ation are good choice as well. In this case, we choosed
dasatinib as a treatment for imatinib resistance.
Conclusions
We detailedly described a man who was co-expression of
the p210 and p190 encoding BCR-ABL transcripts in CMLBC. The presence of p-190 transcript in CML may be
related to progression of the disease. Thus monitoring the
resistance of imatinib in CML patients, especially for ad-
vanced phase CML and BCR-ABL ALL, may be meaningful
to guide clinical treatment and predict the prognosis.
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